Vitrolife Q2 FY26 net income rises 29% to SEK 129 million; net sales fall 2% to SEK 857 million

• Vitrolife posted Q2 net income of SEK 129 million, rising 29% year on year; EPS increased 28% to SEK 0.95.
• Net sales slipped 2% to SEK 857 million; gross margin widened 2.3 percentage points to 60.3%.
• EBITDA climbed 21% to SEK 295 million; the margin expanded 6.6 percentage points to 34.4%.
• Management cited portfolio rationalisation, cost control including headcount reductions, strategic pricing; IVF cycle demand remained soft globally.
• The board launched a share repurchase program of up to SEK 500 million, running from July 17 until the next AGM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitrolife AB published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.